Tag: Biotech and Pharma

Στο πλαίσιο της συμφωνίας, η FAMAR θα αναλάβει, ως αποκλειστικός πάροχος, την παραγωγή των αναλγητικών φαρμακευτικών προϊόντων Lonarid N® και Lonalgal® της Lavipharm.

Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations.

Johnson & Johnson said on Monday it had agreed to buy drug developer Ambrx Biopharma  for $2 billion to gain access to drugs that belong to a class of targeted cancer therapies which have drawn interest from other drugmakers.

Eli Lilly and Co on Thursday launched a website to help people with obesity get prescriptions through telehealth providers and provide home delivery of its weight-loss medicines.

Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

 Bristol Myers Squibb  on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising experimental schizophrenia drug to help power growth as patents on its older therapies expire later this decade.

Moderna on Thursday unveiled new data from a continuing early-stage trial of the personalized cancer treatment it is testing with Merck, saying that the updated results help build the case that the drug works.

Dec 13 (Reuters) – Pfizer on Wednesday forecast 2024 revenue and profit below Wall Street expectations, sending its shares down 7% in premarket trading even as it raised cost-cut target by $500 million.

Icosavax stock soared 47% in Tuesday premarket trading after the Seattle-based vaccine developer reached a deal to be acquired by pharmaceutical giant AstraZeneca.

Dec 6 (Reuters) – AbbVie said on Wednesday it would buy Cerevel Therapeutics , a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.

Πολύ πιθανή η απόκτηση ενός ακόμη ιδιαίτερα γνωστού προϊόντος σε σχετικά σύντομο χρονικό διάστημα, τονίζουν κύκλοι της εταιρείας. Υψηλές οι προσδοκίες για το 2024.

Johnson & Johnson stock was edging higher after the pharmaceutical and medical-device company shared its long-term financial outlook.

Roche has agreed to buy obesity-drug developer Carmot Therapeutics for up to $3.1 billion.

Την υπογραφή συμφωνίας με τη Boehringer Ingelheim International GmbH για την εξαγορά των δύο αναλγητικών φαρμακευτικών προϊόντων Lonarid N® και Lonalgal® για την αγορά της Ελλάδας και της Κύπρου με τη δυνατότητα να τα αξιοποιήσει και διεθνώς ανακοίνωσε σήμερα η Lavipharm A.E.

Pfizer Inc.’s stock tumbled 4% premarket Friday, after the company said it would not move to a Phase 3 trial of a twice-daily formulation of a weight-loss drug after patients in an earlier study had a lot of side effects.

Nov 30 (Reuters) – AbbVie said on Thursday it will buy drugmaker ImmunoGen for $10.1 billion, adding a promising drug for ovarian cancer to its portfolio of oncology treatments.

FRANKFURT, Nov 28 (Reuters) – Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business.

Bayer shares plunged to their lowest level in more than a decade after the group abandoned a key late-stage trial of a blood-thinning drug that was seen as a prospective blockbuster, saying it did not work as hoped.

Shares of Eli Lilly & Co. rose 0.67% in premarket trading Friday after drug giant announced plans to spend $2.5 billion to build a new manufacturing facility in Germany.

LONDON/COPENHAGEN, Nov 10 (Reuters) – Obesity drug maker Novo Nordisk said on Friday it will spend $6 billion to boost production in Denmark, although its chief executive warned the industry was far from being able to produce enough weight-loss drugs to meet global demand.